What this pack is
MEDROL is the brand name in this record; methylprednisolone is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
MEDROLGeneric namemethylprednisolone
How this medicine works
The MEDROL label identifies methylprednisolone as a glucocorticoid. Glucocorticoids can produce broad metabolic, anti-inflammatory and immune-related effects. That helps explain why the label spans several organ systems and why the word “anti-inflammatory” cannot determine an individual's tablet count, duration or stopping method.
Read source: United States ↗Current regulatory record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- MEDROL
- Generic name
- methylprednisolone
- Dosage-form class
- MEDROL methylprednisolone oral tablets: 2, 4, 8, 16 and 32 mg; the current U.S. label also lists a 4 mg 21-tablet unit-dose Dosepak carton
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
6 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 2 mg per tablet; 100-tablet bottle
- Product code
- NDC 0009-0020-01
- Form and route
- MEDROL methylprednisolone oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 2 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 100 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 2Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 4 mg per tablet; 100-tablet bottle
- Product code
- NDC 0009-0056-02
- Form and route
- MEDROL methylprednisolone oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 4 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 100 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 4Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 4 mg per tablet; one 21-tablet unit-of-use blister carton
- Product code
- NDC 0009-0056-04
- Form and route
- MEDROL Dosepak methylprednisolone 4 mg oral tablet · oral (product-identity field)
- Container
- unit-of-use blister carton
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 4 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 21 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 4Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 8 mg per tablet; 25-tablet bottle
- Product code
- NDC 0009-0022-01
- Form and route
- MEDROL methylprednisolone oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 8 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 25 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 8Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 16 mg per tablet; 50-tablet bottle
- Product code
- NDC 0009-0073-01
- Form and route
- MEDROL methylprednisolone oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 16 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 50 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 16Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed public label (revised Nov 2025)
Methylprednisolone 32 mg per tablet; 25-tablet bottle
- Product code
- NDC 0009-0176-01
- Form and route
- MEDROL methylprednisolone oral tablet · oral (product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-08-28; actual marketing, stock and availability are not established.
- methylprednisolone
- 32 mglabelled amount per tablet; not an individual's tablet count, frequency, taper or stopping instruction
- Package
- 25 tablets per pack
- Labelled appearance
- white · elliptical scored tablet; the score is an appearance clue, not permission to self-split · imprint MEDROL 32Scored appearance; this is not a self-splitting instruction
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
MEDROL label reading: milligrams, tablet count, Dosepak rows and stopping are different questions
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current U.S. label lists five per-tablet strengths and one 21-tablet Dosepak. The key boundary is that package identity is not an individual regimen; a glucocorticoid must not be abruptly self-stopped, extended, tapered or replaced because symptoms improve, an adverse effect is feared or another strength is seen.
- 2, 4, 8, 16 and 32 mg are labelled amounts of methylprednisolone per tablet; 100, 25, 50 or 21 are package counts. These two kinds of numbers cannot be multiplied, divided or turned by experience into anyone's daily tablet count.
- The 4 mg Dosepak carton prints day rows, but they belong only to that exact pack. Do not copy the rows to another person, condition, methylprednisolone pack, corticosteroid or market product; follow the individual's prescription and treating team's instructions.
- The label covers infection risk, immunosuppression, vaccines, glucose, gastrointestinal, eye, mood and sleep concerns. Older people, people with several conditions, or those using glucose-lowering, anticoagulant/antiplatelet, pain, diuretic or immunosuppressive medicines, or receiving vaccines, should bring the complete medicine list for active review.
- Severe breathing difficulty; swelling of the face, lips, tongue or throat; altered consciousness; marked infection signs; black stools or vomiting blood; sudden vision change; or another severe rapidly worsening problem requires local emergency or urgent medical help immediately. Do not wait for a web response.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. MEDROL methylprednisolone public label (Pfizer; revised Nov 2025) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-28FDA Drugs@FDA: MEDROL NDA 011153 application record ↗Current regulatory record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about MEDROL (methylprednisolone). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
MEDROL is the brand in this record and methylprednisolone is the active-ingredient name. Check both with the dosage form (MEDROL methylprednisolone oral tablets: 2, 4, 8, 16 and 32 mg; the current U.S. label also lists a 4 mg 21-tablet unit-dose Dosepak carton) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. MEDROL methylprednisolone public label (Pfizer; revised Nov 2025) ↗Current regulatory record · reviewed 2026-08-28
- FDA Drugs@FDA: MEDROL NDA 011153 application record ↗Current regulatory record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How methylprednisolone works: a glucocorticoid that affects inflammatory and immune responses
- It is not an antibacterial medicine, and fever, pain, rash, cough or swelling alone cannot establish suitability. Suppressing inflammatory responses may also affect infection presentation, so the cause and management require clinical assessment.
- Being corticosteroid-related, like prednisone, dexamethasone, hydrocortisone or injectable methylprednisolone, does not make products self-convertible, combinable or interchangeable by milligrams. Ingredient, potency, dosage form, route and regimen each require review.
- Mechanism cannot determine whether, how quickly or when an individual should taper or stop. Especially after longer or repeated use, with multiple conditions or new symptoms, contact the prescribing team rather than building a plan from package rows or an online example.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. MEDROL methylprednisolone public label (Pfizer; revised Nov 2025) ↗Current regulatory record · reviewed 2026-08-28
- FDA Drugs@FDA: MEDROL NDA 011153 application record ↗Current regulatory record · reviewed 2026-08-28
SOURCE-TRACEABLE ARCHIVE
MEDROLmethylprednisolone
This page includes an exact current U.S. public-label package panel for MEDROL, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
MEDROL U.S. initial-approval year
The current DailyMed label lists 1957 as MEDROL's Initial U.S. Approval. This locates U.S. brand history and does not automatically establish approval, trade name, packaging, supply or interchangeability in Mainland China or another market.
DailyMed (NLM): current U.S. MEDROL methylprednisolone public label (Pfizer; revised Nov 2025) ↗Current U.S. MEDROL public label revised
The current label separately lists 2, 4, 8, 16 and 32 mg oral tablets plus the exact NDC and package panel for the 4 mg 21-tablet Dosepak. The date identifies a label version, not an individual's start, duration, taper or stopping date.
DailyMed (NLM): current U.S. MEDROL methylprednisolone public label (Pfizer; revised Nov 2025) ↗
MARKET SCOPE
Market-record boundary
United States
NDA 011153, current label and six exact package identities linkedThe dossier separately retains five per-tablet strengths, six NDCs, bottle counts and the 4 mg Dosepak carton. It supports product identity and safety reading; it does not authenticate a product or establish stock, purchase, individual tablet count, duration, taper, missed-use or stopping instructions.
Mainland China, the EU, Japan and other markets
Current market record not establishedNo local trade name, approval, package, supply, originator/generic relationship, authenticity or interchangeability is inferred from the U.S. NDA, MEDROL name, shared ingredient, tablet score, milligrams, Dosepak rows or package image; each market requires separate review against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Do the rows on a Dosepak carton apply to everyone?
No. The rows belong to the exact 4 mg 21-tablet package identity and cannot be copied to another person, condition, methylprednisolone pack or corticosteroid. An individual plan must come from that person's prescription and treating team.
Does a tablet score permit self-splitting or milligram conversion to another corticosteroid?
No such conclusion follows from a score or milligram number. The score is only an appearance clue here; dosage form, potency, prescription, course, taper and stopping all require professional review of the exact product and individual context.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.